Scope, Claims, and US Patent Landscape for US Patent 8,748,413 (Bz-HC Salt Compositions)
US Patent 8,748,413 covers pharmaceutical compositions that use a salt of a specific hydrocodone conjugate, “benzoate-hydrocodone” (Bz-HC), with additional claim layers on (i) therapeutic use, (ii) oral pharmacokinetics and release behavior, (iii) reduced side-effect profiles (notably gastrointestinal dysfunction), (iv) dosage forms and excipients, (v) PK equivalence thresholds (AUC, Cmax), (vi) broad and granular salt identity lists, (vii) conjugate-to-salt ratios, (viii) dosage amounts, and (ix) packaging into kits. The claim set is drafted to support multiple commercial product formats while maintaining a single chemistry and PK core.
What is the claim nucleus in US 8,748,413?
Core definition
The invention is anchored on:
- Conjugate identity: benzoate-hydrocodone (Bz-HC)
- Form: a “salt of the conjugate”
- Composition type: a pharmaceutical composition
All downstream claims depend on claim 1’s structural premise (Bz-HC) and the presence of a salt form.
Key claim architecture
The claim tree uses a common pattern:
- Claim 1: chemical construct and composition
- Claims 2-5: therapeutic indications + side-effect reduction mapping
- Claims 6-8: dosage forms and excipient categories
- Claims 9-11: oral PK equivalence and Cmax control
- Claims 12-16: salt selection breadth + specific preferred ratios
- Claims 17-19: dose range and kit configuration
This structure supports enforcement across:
- salt selection (wide),
- formulation (wide),
- indication framing (broad),
- in vivo performance (PK equivalence language).
How broad is the claim scope for “salt of the conjugate”?
Salt identity breadth (Claim 12)
Claim 12 enumerates a very large set of potential counterions/salt types. It includes common inorganic and organic acids and many less-common pharmaceutically acceptable salts, with explicit coverage of:
- Benzoate (explicitly listed, including benzoate as one of the salt types, while the conjugate itself is described as benzoate-hydrocodone)
- Hydrochloride/chloride, with direct dependence in Claims 13-16
- A large list spanning acetate, aspartate, besylate, bicarbonate, citrate, edisylate, fumarate, gluconate, hydrobromide, hydrochloride, lactate, malate, mesylate, pamoate, phosphate, succinate, sulfate, tartrate and many others (plus salts including camphorsulfonate variants, napthylates, xinafoate, etc.)
Salt type narrowing via dependency
- Claim 13: “salt is a hydrochloride salt” narrows the salt identity.
- Claims 14-16: specify conjugate-to-salt ratios, including:
- about 1:0.1 to about 1:10 (Claim 14)
- about 1:0.5 to about 1:2 (Claim 15)
- about 1:1 (Claim 16)
Practical scope implication
Even though Claim 13 narrows to hydrochloride, the independent Claim 1 combined with Claim 12 makes the landscape salt-agnostic at baseline (many salts), while simultaneously providing narrower, more enforceable fallbacks tied to hydrochloride plus specific ratio bands.
What therapeutic and abuse-resistance uses are claimed?
Indications and functional objectives (Claim 2)
Claim 2 ties the salt composition to multiple therapeutic and abuse-related objectives:
- Treat narcotic or opioid abuse
- Reduce narcotic or opioid withdrawal
- Treat moderate to severe pain
- Reduce oral, intranasal or intravenous drug abuse
- Provide oral, intranasal or parenteral drug abuse resistance
How these claims behave legally
Because Claim 2 depends on Claim 1, any composition that meets the chemical construct can be argued to fall within this dependent use language, even if the salt is not hydrochloride (unless the dependent claim is further limited).
This is commercially material because it maps directly onto:
- opioid treatment narratives (abuse/withdrawal),
- mainstream analgesic labeling objectives,
- and abuse-deterrent claims for multiple routes (oral, intranasal, parenteral).
What performance claims are made (AUC, rate of release, variability, side effects)?
PK and release improvements (Claim 3)
Claim 3 contains three alternative performance vectors, any one of which can satisfy the claim as written:
- Improved AUC and rate of release over time versus unconjugated hydrocodone over the same period
- Less variability in oral PK profile versus unconjugated hydrocodone
- Reduced side effects versus unconjugated hydrocodone
This claim is written to capture both:
- pharmacokinetic exposure and absorption/release behavior, and
- in vivo tolerability.
Gastrointestinal dysfunction reduction (Claims 4-5)
Claim 4 narrows “reduced side effects” to gastrointestinal dysfunction.
Claim 5 specifies possible gastrointestinal dysfunction embodiments:
- constipation
- decreased hydrochloric acid secretion in the stomach
- decreased gastric motility
- esophageal reflux
- combinations thereof
Practical enforcement posture
Claim 3 and its dependent GI narrowing creates two pathways for infringement arguments:
- PK-based proof: AUC and release kinetics vs unconjugated hydrocodone
- Tolerability-based proof: GI adverse effect reduction, including specific GI endpoints
What dosage forms and formulation elements are covered?
Dosage form list (Claim 6)
Claim 6 allows delivery in a broad set of conventional formats:
- tablet
- capsule
- caplet
- suppository
- troche
- lozenge
- oral powder
- solution
- oral film
- thin strip
- slurry
- suspension
Excipients (Claims 7-8)
- Claim 7: dosage form further comprises at least one excipient
- Claim 8: excipient is selected from a long category list including:
- antiadherent, binder, coating, disintegrant, filler, flavor, color, glidant, lubricant, preservative, sorbent, sweetener
- mixtures and combinations
Scope implication
This formulation language is broad enough to cover most standard oral solid and oral liquid manufacturing routes for salts, without narrowing to any unique excipient system.
What PK equivalence and Cmax controls are explicitly required?
Bioequivalence framing (Claims 9-11)
These claims define quantitative objectives relative to unconjugated hydrocodone:
- Claim 9: amount sufficient to provide therapeutically bioequivalent AUC
- Claim 10: amount sufficient to provide therapeutically bioequivalent AUC and Cmax
- Claim 11: amount sufficient to provide therapeutically bioequivalent AUC and a lower Cmax
Why this matters
The claims support product positioning where exposure is maintained (AUC), while peak exposure (Cmax) is reduced, aligning with:
- tolerability improvement,
- reduced side-effect risk,
- and abuse-related objectives (peak-driven effects can correlate with subjective intensity).
The drafting also permits argument that even if the salt changes the release profile, the dosing can be adjusted to hit exposure equivalence bands.
What dosing and kit coverage is claimed?
Dose amount range (Claim 17)
- composition includes about 0.5 mg to about 100 mg of the salt of the conjugate.
This covers both low-dose and typical analgesic dosing band expansions, depending on hydrocodone equivalent scaling.
Kit configuration (Claims 18-19)
- Claim 18: composition is in a pharmaceutical kit
- Claim 19: kit contains from about 1 to about 100 individual dosages
This supports commercial packaging strategies including:
- single-dose initiation,
- titration regimens,
- or multi-day packs.
US patent landscape: what this claim scope implies for competitive freedom-to-operate
Because the claim text you provided is complete at the level of independent and dependent claim topics, the landscape can be mapped by what categories of alternative designs are still likely to land inside or outside the claim boundaries.
Designs likely to be captured
A competitor is at high risk of falling within the literal claim space if they implement:
- Benzoate-hydrocodone (Bz-HC) conjugate
- Any salt form of that conjugate (per broad salt list)
- A dosage form in the enumerated list (tablets/capsules/oral films/solutions/suspensions/suppositories, etc.)
- Dosing strategies that aim for AUC equivalence vs unconjugated hydrocodone, and optionally lower Cmax
- Claims or labeling positioned around opioid abuse/withdrawal, abuse resistance (oral/intranasal/parenteral), or moderate to severe pain
- Formulation that is conventional with typical excipient categories
Designs that can fall outside (conceptually)
A competitor can avoid literal capture by departing from at least one mandatory element:
- Not using Bz-HC conjugate (changing the conjugation chemistry likely avoids the nucleus)
- Not using a “salt of the conjugate” (for example, free base or a different molecular construct, if it can be credibly argued)
- Changing dosage form outside the enumerated list (though most mainstream oral forms remain covered)
- Avoiding the specific PK equivalence and/or Cmax objectives if the claims are interpreted tightly on quantitative performance
In practice, because Claims 9-11 are “provided in an amount sufficient” to achieve bioequivalence targets, the claim is written to let an accused product be argued into scope through PK matching rather than only by composition formula.
Where are the “enforcement hooks” strongest?
Strongest chemical hooks
- Bz-HC conjugate as the conjugate identity
- Salt form of that conjugate, especially if the accused product is hydrochloride salt (Claim 13) with ratio bands (Claims 14-16)
Strongest performance hooks
- AUC and release kinetics improvements vs unconjugated hydrocodone (Claim 3)
- Less oral PK variability (Claim 3)
- Lower Cmax while maintaining AUC (Claim 11)
- GI adverse effect reduction with explicit GI endpoint list (Claims 4-5)
Strongest product-configuration hooks
- Broad dosage forms (Claim 6)
- Broad excipient category (Claims 7-8)
- Dose range (Claim 17)
- Kit structure (Claims 18-19)
What does the claim coverage mean for investors evaluating competitive risk?
A Bz-HC salt product that hits the claimed performance targets will generally create:
- high litigation leverage for the owner,
- and narrow technical escape routes for competitors who otherwise want opioid exposure with abuse-deterrent or tolerability improvements.
The patent claims are drafted to support both:
- pharmacology-based proof (PK and GI endpoints),
- and manufacturing flexibility (many dosage forms/excipients).
Key Takeaways
- US 8,748,413 is centered on a single chemical construct: benzoate-hydrocodone (Bz-HC) presented as a salt.
- The salt scope is broad (extensive counterion list), with hydrochloride and specific conjugate-to-salt ratios as explicit narrower sub-scope.
- The claims cover opioid abuse/withdrawal and abuse resistance across multiple administration routes, plus moderate to severe pain.
- The claim set relies on PK and tolerability performance: AUC, release rate, oral PK variability, Cmax control, and gastrointestinal dysfunction with explicit endpoints.
- Formulation scope is wide: many dosage forms and excipient categories, plus kit configurations and a broad mg range.
FAQs
1) Is the patent limited to hydrochloride salts?
No. hydrochloride is a dependent narrowing (Claims 13-16), while the independent claim framework covers “a salt of the conjugate” and Claim 12 lists many salt types.
2) Does the patent require lower Cmax?
Not in Claim 1. Claims 9-10 require AUC equivalence (with Cmax equivalence in Claim 10), and Claim 11 requires lower Cmax while maintaining AUC equivalence as an additional dependent limitation.
3) Are gastrointestinal side effects specifically claimed?
Yes. Claim 4 limits “reduced side effects” to gastrointestinal dysfunction, and Claim 5 enumerates constipation, altered gastric hydrochloric acid secretion, reduced gastric motility, and esophageal reflux.
4) Does the patent cover abuse resistance by route?
Yes. Claim 2 includes drug abuse resistance for oral, intranasal, and parenteral administration.
5) Does the patent cover multiple dosage forms?
Yes. Claim 6 lists tablets, capsules, caplets, suppositories, troches, lozenges, oral powders, solutions, oral films/thin strips, slurries, and suspensions.
References
[1] User-provided claim text for US Patent 8,748,413 (claims 1-19).
